Cargando…
RCN1 induces sorafenib resistance and malignancy in hepatocellular carcinoma by activating c-MYC signaling via the IRE1α–XBP1s pathway
The increasing incidence of hepatocellular carcinoma (HCC) is of great concern globally, but the molecular pathogenesis of these tumors remains unclear. Sorafenib is a first-line drug for the treatment of advanced HCC. However, the efficacy of sorafenib in improving patient survival is limited, and...
Autores principales: | Wang, Jia-Wei, Ma, Li, Liang, Yuan, Yang, Xiao-Jun, Wei, Song, Peng, Hao, Qiu, Shi-Pei, Lu, Xu, Zhu, Ya-Qing, Wang, Bao-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523720/ https://www.ncbi.nlm.nih.gov/pubmed/34663798 http://dx.doi.org/10.1038/s41420-021-00696-6 |
Ejemplares similares
-
IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling
por: Sheng, Xia, et al.
Publicado: (2019) -
Role of IRE1α/XBP-1 in Cystic Fibrosis Airway Inflammation
por: Ribeiro, Carla M. P., et al.
Publicado: (2017) -
IRE1α Promotes Zika Virus Infection via XBP1
por: Kolpikova, Elena P., et al.
Publicado: (2020) -
The Role of BiP and the IRE1α–XBP1 Axis in Rhabdomyosarcoma Pathology
por: Aghaei, Mahmoud, et al.
Publicado: (2021) -
Ebola Virus Activates IRE1α-Dependent XBP1u Splicing
por: Rohde, Cornelius, et al.
Publicado: (2022)